GRI Bio (GRI) Competitors $1.86 -0.11 (-5.58%) As of 10/10/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GRI vs. ASBP, AYTU, CLRB, LPCN, PULM, NAII, LEXX, THAR, NRSN, and BLRXShould you be buying GRI Bio stock or one of its competitors? The main competitors of GRI Bio include Aspire Biopharma (ASBP), Aytu BioPharma (AYTU), Cellectar Biosciences (CLRB), Lipocine (LPCN), Pulmatrix (PULM), Natural Alternatives International (NAII), Lexaria Bioscience (LEXX), Tharimmune (THAR), NeuroSense Therapeutics (NRSN), and BioLineRx (BLRX). These companies are all part of the "pharmaceutical products" industry. GRI Bio vs. Its Competitors Aspire Biopharma Aytu BioPharma Cellectar Biosciences Lipocine Pulmatrix Natural Alternatives International Lexaria Bioscience Tharimmune NeuroSense Therapeutics BioLineRx Aspire Biopharma (NASDAQ:ASBP) and GRI Bio (NASDAQ:GRI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership. Which has stronger valuation & earnings, ASBP or GRI? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAspire BiopharmaN/AN/A-$12.54MN/AN/AGRI BioN/AN/A-$8.21M-$11.56-0.16 Do analysts prefer ASBP or GRI? GRI Bio has a consensus target price of $22.50, indicating a potential upside of 1,109.68%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts clearly believe GRI Bio is more favorable than Aspire Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00GRI Bio 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is ASBP or GRI more profitable? Aspire Biopharma's return on equity of 0.00% beat GRI Bio's return on equity.Company Net Margins Return on Equity Return on Assets Aspire BiopharmaN/A N/A -737.96% GRI Bio N/A -327.62%-191.40% Does the media favor ASBP or GRI? In the previous week, Aspire Biopharma had 1 more articles in the media than GRI Bio. MarketBeat recorded 3 mentions for Aspire Biopharma and 2 mentions for GRI Bio. GRI Bio's average media sentiment score of 0.95 beat Aspire Biopharma's score of 0.38 indicating that GRI Bio is being referred to more favorably in the news media. Company Overall Sentiment Aspire Biopharma Neutral GRI Bio Positive Do institutionals and insiders have more ownership in ASBP or GRI? 19.2% of Aspire Biopharma shares are owned by institutional investors. Comparatively, 34.0% of GRI Bio shares are owned by institutional investors. 25.8% of Aspire Biopharma shares are owned by company insiders. Comparatively, 0.9% of GRI Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, ASBP or GRI? Aspire Biopharma has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, GRI Bio has a beta of -1.45, meaning that its share price is 245% less volatile than the S&P 500. SummaryGRI Bio beats Aspire Biopharma on 7 of the 11 factors compared between the two stocks. Get GRI Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GRI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRI vs. The Competition Export to ExcelMetricGRI BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.96M$3.38B$6.11B$10.63BDividend YieldN/A2.29%5.66%4.71%P/E Ratio-0.1621.9785.2726.57Price / SalesN/A462.21612.79132.63Price / CashN/A47.2238.5062.09Price / Book0.2410.2112.726.53Net Income-$8.21M-$52.40M$3.30B$275.96M7 Day Performance-2.62%0.88%0.95%-0.73%1 Month Performance-9.27%10.41%6.35%3.71%1 Year Performance-72.88%27.28%80.42%37.30% GRI Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRIGRI Bio2.4593 of 5 stars$1.86-5.6%$22.50+1,109.7%-71.4%$4.96MN/A-0.161Analyst ForecastASBPAspire BiopharmaN/A$0.38+0.3%N/AN/A$19.01MN/A0.00N/AAnalyst ForecastAYTUAytu BioPharma3.6289 of 5 stars$2.19+15.3%$9.17+318.6%+5.4%$18.83M$66.38M-0.78160Gap UpCLRBCellectar Biosciences2.3367 of 5 stars$6.17+6.7%$375.00+5,977.8%-92.6%$18.45MN/A-0.3110Analyst ForecastHigh Trading VolumeLPCNLipocine3.0985 of 5 stars$3.20-4.5%$8.00+150.0%-40.4%$18.15M$11.20M-3.6810Analyst ForecastHigh Trading VolumePULMPulmatrix0.9428 of 5 stars$5.06+3.9%N/A+121.9%$17.78M$369K-2.3320Positive NewsAnalyst ForecastHigh Trading VolumeNAIINatural Alternatives International1.5254 of 5 stars$2.76-2.1%N/A-41.9%$17.42M$129.86M-1.22290Analyst ForecastLEXXLexaria Bioscience2.8081 of 5 stars$0.84-4.4%$4.00+376.2%-72.0%$17.19M$460K-1.257News CoverageAnalyst ForecastGap DownTHARTharimmune2.4214 of 5 stars$3.03+4.1%$17.00+461.1%+46.1%$17.18MN/A-0.502News CoverageAnalyst ForecastNRSNNeuroSense Therapeutics2.2216 of 5 stars$1.17-6.4%$14.00+1,096.6%+0.0%$17.08MN/A-2.1710Analyst ForecastBLRXBioLineRx2.9905 of 5 stars$4.22+5.5%$26.00+516.1%-79.1%$17.05M$28.94M-0.4840Analyst Forecast Related Companies and Tools Related Companies ASBP Alternatives AYTU Alternatives CLRB Alternatives LPCN Alternatives PULM Alternatives NAII Alternatives LEXX Alternatives THAR Alternatives NRSN Alternatives BLRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRI) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GRI Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GRI Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
